AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Anika to Participate in Two Investor Events in May 2019

May 6, 2019

BEDFORD, Mass.--(BUSINESS WIRE)--May 6, 2019--Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced that the Company will participate in the following two investor events in May:

  • Deutsche Bank 44 th Annual Health Care Conference on Tuesday, May 7, 2019 at The InterContinental Hotel in Boston.
  • Singular Research Spring Select Web Call on Thursday, May 30, 2019.

A live audio webcast of the Singular Research Spring Select Web Call may be accessed via the Investor Relations section of Anika’s website at www.anikatherapeutics.com. An audio archive of the presentation also will be available on the website.

About Anika Therapeutics, Inc.
Anika Therapeutics, Inc.  (NASDAQ: ANIK) is a global, integrated orthopedic and regenerative medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative tissue repair. The Company has over two decades of global expertise developing, manufacturing, and commercializing more than 20 products based on its proprietary  hyaluronic acid (HA) technology. Anika’s orthopedic medicine portfolio includes  ORTHOVISC®MONOVISC®, and  CINGAL®, which alleviate pain and restore joint function by replenishing depleted HA, and  HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. For more information about Anika, please visit  www.anikatherapeutics.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190506005365/en/

CONTACT: For Investor Inquiries:

Anika Therapeutics, Inc.

Sylvia Cheung, 781-457-9000

Chief Financial Officer

For Media Inquiries:

W2O Group

Sonal Vasudev, 917-523-1418

sonal@w2ogroup.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL OTHER HEALTH

SOURCE: Anika Therapeutics, Inc.

Copyright Business Wire 2019.

PUB: 05/06/2019 08:30 AM/DISC: 05/06/2019 08:30 AM

http://www.businesswire.com/news/home/20190506005365/en